Product-to-Claim Mapping: Delhi HC Vacates Biosimilar Injunction on Cancer Drug
The Delhi High Court's Division Bench held that product-to-claim mapping is indispensable for patent infringement, even in anticipatory suits. In a dispute between Zydus Lifesciences and E.R. Squibb over a biosimilar of the cancer drug Nivolumab, the court vacated an…









